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Abstract
OBJECTIVES: The CD26 antigen is a transmembrane glycoprotein that is constitutively expressed on activated lymphocytes and in pul-
monary parenchyma. This molecule is also identiﬁed as dipeptidyl peptidase-4 (DPP-4) that cleaves a host of biologically active pep-
tides. Here, we aimed to identify an important substrate of CD26/DPP-4—stromal cell-derived factor-1 (SDF-1/CXCL12)—as a key
modulator for stem-cell homing together with its receptor CXCR4 in response to ischaemic injury of the lung.
METHODS: Orthotopic single lung transplantation (Tx) was performed between syngeneic C57BL/6 mice. Inhibition of CD26/DPP-4 ac-
tivity in recipients was achieved using vildagliptin (10 mg/kg, every 12 h) subcutaneously, and 6 h ischaemia time was applied prior to
implantation. Forty-eight hours after Tx, lung histology, SDF-1 levels (enzyme-linked immunosorbent assay) in lung, spleen and plasma,
and expression of the SDF-1 receptor CXCR4 in blood and lung were assessed. Homing of regenerative progenitor cells to the trans-
planted lung was evaluated using fluorescent-activated cell sorting.
RESULTS: Compared with untreated lung transplanted mice, systemic DPP-4 inhibition of Tx recipients resulted in an increase in protein
concentration of SDF-1 in plasma, spleen and lung. Concordantly, the frequency of cells bearing the SDF-1 receptor CXCR4 rose signiﬁ-
cantly in the circulation and also in the lungs of DPP-4-inhibited recipients. We found co-expression of CXCR4/CD34 in the grafts of
animals treated with vildagliptin, and the stem-cell markers Flt-3 and c-kit were present on a signiﬁcantly increased number of cells. The
morphology of grafts from DPP-4 inhibitor-treated recipients revealed less alveolar oedema when compared with untreated recipients.
CONCLUSIONS: Targeting the SDF-1–CXCR4 axis through CD26/DPP-4 inhibition increased the intragraft number of progenitor cells con-
tributing to the recovery from ischaemia-reperfusion lung injury. Stabilization of endogenous SDF-1 is achievable and may be a promising
strategy to intensify sequestration of regenerative stem cells and thus emerges as a novel therapeutic concept.
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INTRODUCTION
CD26 is a type II transmembrane glycoprotein that exerts potent
co-stimulatory effects on signalling lymphocytic activation [1]. This
molecule has an extra-membranous catalytic domain, dipeptidyl
peptidase-4 (DPP-4), that possesses exopeptidase activity. DPP-4
is constitutively expressed on many haematopoietic cells includ-
ing activated T- and B-lymphocytes, capillary endothelial cells [2],
epithelial cells and stem cells [3], but is also found in a catalytically
active soluble form in plasma [4]. DPP-4 cleaves N-terminal
dipeptides from peptides where usually proline or alanine resides
at the penultimate position. A wide range of chemokines, growth
factors, neuropeptides and other key biological peptides are
subject to cleavage by DPP-4 [5]. In the wake of investigating the
in vivo catalytic activity of DPP-4, we recently identiﬁed pulmon-
ary vasoactive intestinal peptide (VIP) as crucial for ameliorating
ischaemia reperfusion (I/R) in a rat transplantation (Tx) model [6].
This concept could be reproduced in the mouse model of lung Tx
where the inhibition of DPP-4 intragraft enzymatic activity led to
an enhancement of VIP levels and a preservation and profound
regeneration of the pulmonary function [7].
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Among many other peptides that are cleaved by DPP-4, the
chemokine stromal cell-derived factor-1 (SDF-1/CXCL12) consti-
tutes the most important protein for the recruitment and
homing of bone marrow-derived regenerative stem cells
throughout the mammalian system [8]. Along with its receptor
CXCR4, it forms an axis that is highly conserved in humans and
mice [9]. The modulation of the SDF-1 and CXCR4 axis was
demonstrated to improve stem-cell engraftment following injury
[10–12]. This mechanism of stem-cell homing is not restricted to
a speciﬁc organ. Concentrations of SDF-1 are increased in bleo-
mycin lung injury [13] and, upon hypoxia, SDF-1 reacts with
heightened CXCR4 expression resulting in an enhanced che-
moattractive response [14]. Furthermore, experimental evidence
suggested that pharmacological inhibition of DPP-4 improved
heart function [15] and increased survival in a heterotopic heart
Tx model [16].
We hypothesize here that inhibition of DPP-4 retards the deg-
radation of SDF-1 and thereby (i) stabilizes systemic and intra-
graft levels of SDF-1, (ii) recruits regenerative progenitor cells to
the site of injury through an enhanced SDF-1–CXCR4 axis and
(iii) improves the recovery of the transplanted organ. In order to
address these questions, we orthotopically transplanted single
lungs between syngeneic BL/6 mice, determined protein con-
tents of SDF-1 in circulation and Tx lungs, analysed the circulat-
ing and intragraft CXCR4 expression and regenerative progenitor
cells, and ﬁnally evaluated the outcome of the Tx grafts after 48 h.
The groups of analysis comprised: wild-type animals that were
neither transplanted nor inhibitor-treated (WT); CD26 knockout
animals that were also neither transplanted nor inhibitor-treated
(CD26/DPP-4 KO); single lung-transplanted animals (Tx); and
single lung-transplanted animals that received the
DPP-4-inhibitor vildagliptin subcutaneously (Tx-inhibited).
MATERIALS AND METHODS
Mice
Speciﬁc pathogen-free inbred male mice, strain C57BL/6 (H2b)
(Harlan, Horst, The Netherlands), weighing 25–32 g, were used.
CD26/DPP-4 KO mice (on a C57BL/6 background) were
obtained from Taconic (Taconic, Bomholt, Denmark) with ap-
proval from Dr D. Marguet (Centre d’Immunologie de Marseille
Luminy-INSERM, Marseille Luminy, France) [17]. Animals
received adequate care in strict accordance with the Principles
of Laboratory Animal Care (National Institutes of Health
Publication No. 85-23, promulgated in 1985, most recently
revised in 1996), and the study was approved by the local veter-
inary ethical committee under the study number 177/2010.
Experimental setting
Orthotopic, single-lung Tx between C57BL/6 mice was per-
formed as described before [18]. Treated animals (n = 3–6)
received vildagliptin (custom synthesized by GLSynthesis, Inc.,
Worcester, MA, USA), at a dose of 10 mg/kg (diluted in 0.9%
NaCl solution to achieve a ﬁnal injection volume of 400 μl) sub-
cutaneously immediately before Tx, and every 12 h thereafter
(Tx-inhibited), whereas controls (n = 3–6) did not receive any
treatment upon transplantation (Tx). The donor graft was
exposed to 6 h cold ischaemia time before transplantation. All
grafts were analysed 48 h after Tx, animals receiving neither
DPP-4 inhibitor treatment nor undergoing lung transplantation
are indicated as wild-type animals (WT) and CD26/DPP-4 knock-
out animals (CD26/DPP-4 KO).
Lung recovery
Before sacriﬁce, animals were intubated, anaesthetized and a
laparosternotomy was performed as described [18]. Ventilation
was maintained applying a tidal volume of 1 ml with a positive
end-expiratory pressure of 2 mbar remaining unchanged until
removal of the heart and lungs. The lungs were ﬂushed with 10 ml
of 0.9% normal saline solution at a pressure of 10 cm H2O via
the pulmonary artery, and organs were subsequently removed.
Magnetic resonance imaging
Magnetic resonance (MR) imaging of the mouse lung was con-
ducted on a 4.7 T small animal scanner (Bruker BioSpec,
Switzerland) using a transmit–receive radiofrequency coil with a
three-dimensional ultrashort echo time sequence.
Histology, H&E
Tx lungs and Tx-inhibited lungs were ﬁxated in 4% phosphate-
buffered formalin, cut and embedded in parafﬁn. Sections of
4 μm thickness were cut and stained for haematoxylin & eosin
(H & E).
DPP-4 activity assay
DPP-4 enzymatic activity was assayed in mouse plasma and lung
homogenates (homogenization protocol as described earlier [2])
using glycyl-prolyl-4-methoxy-β-naphthylamide (Gly-Pro-4-Me-β-NA)
as ﬂuorogenic substrate according to Scharpé et al. [19]. In a
96-well plate, 5-µl samples were mixed with 0.5 mM
Gly-Pro-4-Me-β-NA in 50 mM Tris buffer, pH 8.3, in a ﬁnal
volume of 110 µl. DPP-4 activity was determined kinematically
for 10 min at 37°C by measuring the velocities of 4-Me-β-NA
release (λex = 340 nm, λem = 430 nm) from the substrate using an
Inﬁnite™ 200 (Tecan Group Ltd, Switzerland). Fluorescence in-
tensity was related to a 4-Me-β-NA standard curve. The revers-
ibility of the DPP-4 inhibitor, vildagliptin, in the samples and the
dilution of these samples in the assay result in an underestima-
tion of the DPP-4 inhibition. Therefore, a calibration curve was
created with known concentrations of the inhibitor in mouse
plasma to estimate the percentage of the in vivo inhibition (all
reagents are from Sigma-Aldrich, Germany).
Enzyme-linked immunosorbent assay for SDF-1
Plasma, lung and spleen were collected at autopsy and stored at
−80°C. Spleen and lungs were homogenized in ice-cold lysis
buffer [1% Triton X-100 in Dulbecco’s phosphate-buffered saline,
pH 7.4, containing 1 mM ethylenediaminetetraacetic acid (EDTA)
and protease inhibitor cocktail (P-2714; Sigma-Aldrich (1:10)].
Fifty milligrams of the tissue were homogenized in 50 μl of lysis
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buffer using a micro tissue grinder. The material was then centri-
fuged for 10 min at 14 000 rpm and 4°C. The protein concentration
in the collected supernatant was estimated using the DC protein
assay (Bio-Rad Laboratories, Reinach, Switzerland) with bovine
serum albumin as a standard. To assess the concentration of
CXCL12/SDF-1alpha, we used the Quantikine sandwich enzyme-
linked immunosorbent assay from R&D system (cat MCX120; de-
tection limit of 156 pg/ml). We tested 50 μl of diluted tissue lysate
containing 0.5 mg of proteins. The remaining steps were performed
according to the manufacturer’s protocol. All results were expressed
in pg/mg protein for lung and spleen analysis.
Flow cytometry of peripheral blood and single
cells from lung transplants
Single-cell suspensions from transplanted lungs were prepared
as follows: lungs were meshed and collected in 5 ml of Roswell
Park Memorial Institute (RPMI) with 10% foetal calf serum and
50 μg/ml gentamicin, after which they were incubated in 0.5 ml
of collagenase (147 units/mg) (PAN Biotech, Aidenbach,
Germany) (2 mg/ml collagenase II in RPMI) for 30 min at 37°C.
The collagenase reaction was stopped by adding 1 ml of 1 M
EDTA and cells were then ﬁltered through a 70-μm cell strainer.
Cells and full blood samples were stained with following anti-
bodies: CD45-PB, CD26-FITC, CD34-FITC, CD184 (CXCR4)-PE,
CD117 (c-kit)-PE and Flt-3-PE (all Abs from BD Pharmingen,
Allschwil, Switzerland) and subjected to ﬂow cytometry using BD
SORP ﬂow cytometer, LSRII Fortessa. Between 30 000 and 200
000 events were analysed for each sample.
Statistics
Data analysis was performed using SPSS for Windows 15.0 (SPSS,
Inc., Chicago, IL, USA). For group comparison of more than two
groups, the Kruskal–Wallis test was performed, and to compare
the differences between two groups, the Mann–Whitney U-test
was performed. A P-value of <0.05 was considered to be statis-
tically signiﬁcant.
RESULTS
DPP-4 activity in plasma and lung homogenates
In order to prove that the subcutaneous application of the
DPP-4 inhibitor vildagliptin had an effect not only in the periph-
eral circulation, but also in the lungs, we determined the activity
of DPP-4 in plasma and lung homogenates (Fig. 1). In the WT
animal, plasma DPP-4 activity (6.1 U/l), being the physiological
activity, was the highest. The activity diminished after transplant-
ation (2.5 U/l) and was even lower in a Tx-inhibited animal (1.3
U/l). The DPP-4 activity in plasma derived from a CD26/DPP-4
KO mouse was almost undetectable (0.3 U/l) (Fig. 1a). The per-
centage of in vivo DPP-4 activity in the Tx-inhibited animals
compared with the Tx animals was estimated for both plasma
and lung and is 20 and 26%, respectively (Fig. 1b). This estima-
tion is a way to compensate for the sample dilution and thus
underestimation of the actual in vivo inhibition by the reversible
DPP-4 inhibitor.
CD26 receptor expression in peripheral blood
CD26 receptor expression on CD45+ haematopoietic cells
showed an equal distribution between Tx (12.9%) and
Tx-inhibited mice (11.9%) (Fig. 2).
SDF-1 protein levels in the lungs
WT lungs revealed low levels of SDF-1 protein (229 ± 36.8 pg/
mg). In Tx animals, we found an increase in the SDF-1 concen-
tration (480.1 ± 96.9 pg/mg), but grafts from Tx-inhibited animals
showed signiﬁcantly higher levels (715 ± 34.4 pg/mg; P < 0.05).
Finally, lungs from CD26/DPP-4 KO mice had the highest
concentration of SDF-1 (808.1 ± 37.8 pg/mg) (Fig. 3).
CXCR4 is enhanced in the peripheral blood of
DPP-4 inhibitor-treated recipients
We observed a more than 9-fold increase in CXCR4+/CD45+
haematopoietic cells in peripheral blood of Tx-inhibited (49.8 ±
3.2%) compared with Tx animals (5.6 ± 1.1%) (Fig. 4). This differ-
ence was signiﬁcant between both groups (P < 0.05).
Figure 1: (a) Bar graphs indicating the plasma DPP-4 activity of a wild-type
(WT), transplanted (Tx), Tx-inhibited and CD26/DPP-4 KO animal (n = 1 for
each condition). The activity was measured 12 h after the last subcutaneous
application of 10 mg/kg vildagliptin. (b) Bar graphs indicating the estimated
percentage in vivo DPP-4 activity in plasma and lung homogenates of a Tx
and Tx-inhibited animal (n = 1 for each condition). Plasma samples and lungs
were collected 48 h after Tx.
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CXCR4 and CD34 are co-expressed in
transplanted lungs of DPP-4 inhibitor-treated
recipients
Not only in peripheral blood, but also in the transplanted lung,
CXCR4 was expressed on CD45+ haematopoietic cells in signiﬁ-
cantly higher frequencies in Tx-inhibited animals (14.7 ± 3.5%)
compared with Tx animals (7.9 ± 1.8%; P < 0.05). We were then
interested in the presence of the marker of endothelial progenitor
cells, CD34. When looking for its co-expression with CXCR4, we
found a distinct cell population on CD45+ haematopoietic cells
that displayed both markers at the cell surface. They homed into
the transplanted lungs of Tx-inhibited mice (16.6 ± 2.2%) (Fig. 5).
Regenerative progenitor cells are increased in
transplanted lungs of DPP-4 inhibitor-treated
recipients
When staining the regenerative progenitor marker Flt-3 on
CD45+ haematopoietic cells, they were found to be expressed in
signiﬁcantly higher frequencies in Tx-inhibited lungs (12.8 ±
1.8%) than in Tx lungs (1.6 ± 0.2%; P < 0.05) (Fig. 6). When add-
itionally looking for the co-expression of Flt-3 and CD34, we
found a distinct cell population among the CD45+ haematopoi-
etic cells that displayed both markers at the cell surface and that
homed into Tx-inhibited lungs (14.4 ± 1.7%) (Fig. 6). Finally, the
stem-cell marker c-kit (CD117) was found to be expressed sig-
niﬁcantly higher in Tx-inhibited lungs (7.3 ± 1.8%) compared with
Tx lungs (1.3 ± 0.2%; P < 0.05) (Fig. 7).
Transplanted lungs of DPP-4 inhibitor-treated
recipients display less ischaemic injury
The macroscopic appearance of syngrafted Tx lungs (Fig. 8a) vs.
Tx lung from animals that were inhibited (Fig. 8b) appeared
more inﬂamed and oedematous. MR images showed a lower
transparency in Tx lungs (Fig. 8c) when compared with Tx lung
from animals that were inhibited (Fig. 8d). When comparing the
histological morphology of the transplanted lungs between the
DPP-4 inhibitor-treated and untreated group, grafts from the un-
treated group showed a certain degree of congestion and con-
siderable oedema of alveolar cells, whereas the grafts from the
treated group showed a near-normal alveolar wall and cellular
ultrastructure (Fig. 8e and f).
DISCUSSION
We provide evidence that pharmacological inhibition of the
DPP-4 activity leads to (i) decreased systemic activity of DPP-4,
(ii) stabilization of SDF-1 in the transplants, (iii) upregulation of
its receptor CXCR4 in the transplants and (iv) homing of regen-
erative progenitor cells to the transplant with (v) better recovery
from I/R injury.
As a proof of concept, we measured the activity of DPP-4 in
plasma as well as lung homogenates. Inhibition of the DPP-4 ac-
tivity by vildagliptin could be detected in both compartments.
The plasma DPP-4 activity was higher in WT mice compared
with Tx mice. The reason for the decreased activity upon syn-
geneic transplantation remains largely speculative. A similar de-
crease in plasma DPP-4 activity has been reported earlier in
syngeneic heart transplantation, whereas in recipients of allogen-
eic grafts, plasma DPP-4 activity was increased [20]. Apart from
the measurement of activity, ﬂuorescent-activated cell sorting
Figure 2: FACS analysis showing the percentages of the presence of the CD26-receptor on CD45+ cells in peripheral blood of transplanted (Tx) and Tx-inhibited
animals taken 48 h after Tx (n = 1 for each condition).
Figure 3: The SDF-1 protein levels in lung homogenates for different experi-
mental conditions: wild-type (WT), transplanted (Tx), Tx-inhibited and CD26/
DPP-4 KO. Data represent mean ± SD (n = 3); *P < 0.05.
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(FACS) analysis of the CD26 protein expression on haematopoi-
etic cells revealed an equal distribution in both, the Tx and
Tx-inhibited mice. This ﬁnding suggests that vildagliptin does not
affect the CD26 receptor expression on cells. The T-cell-
mediated immune response, which is also involved in the
defence mechanism after I/R injury, is therefore believed to be
essentially unaltered [1].
Under steady-state conditions, SDF-1 is not only constitutively
expressed in spleen, but also present in small concentrations in
the lung. However, levels are enhanced upon ischaemia and
Figure 4: Representative FACS analysis showing the mean percentages of CD45+CXCR4+ cells in peripheral blood of transplanted (Tx) and Tx-inhibited animals
taken 48 h after Tx, the latter showing a signiﬁcantly higher cell frequency (*P < 0.05); data represent mean ± SEM (n = 4).
Figure 5: Representative FACS analysis showing the mean percentages of CD45+CXCR4+ cells in lung homogenates of transplanted (Tx) and Tx-inhibited animals,
the latter showing a signiﬁcantly higher cell frequency (*P < 0.05); data represent mean ± SEM (n = 4). Gating of CD45+CXCR4+ cells for CD34 revealed a distinct
population of CD34+CXCR4+ double positive cells in lung homogenates of Tx-inhibited animals.
Figure 6: Representative FACS analysis showing the mean percentages of CD45+Flt-3+ cells in lung homogenates of transplanted (Tx) and Tx-inhibited animals, the
latter showing a signiﬁcantly higher cell frequency (*P < 0.05); data represent mean ± SEM (n = 4). Gating of CD45+Flt-3+ cells for CD34 revealed a distinct popula-
tion of CD34+Flt-3+ double positive cells in lung homogenates of Tx-inhibited animals.
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hypoxia [21, 22]. It has been shown that SDF-1 gene expression
in ischaemic tissue is directly proportional to reduced oxygen
tension via upregulation of hypoxia-inducible factor 1 [22]. This
increased SDF-1, which is released from ischaemic endothelial
cells, contributes to stem-cell mobilization from bone marrow
[23]. Accordingly, we could observe an injury-induced increase
Figure 7: Representative FACS analysis showing the mean numbers of CD45+c-kit+ cells in lung homogenates of transplanted (Tx) and Tx-inhibited animals, the
latter showing a signiﬁcantly higher cell frequency (*P < 0.05); data represent mean ± SEM (n = 4).
Figure 8: Representative syngrafts from transplanted (Tx) lungs (a) vs. Tx lung from animals that were inhibited (b), macroscopically appeared more inﬂamed and
oedematous (n = 4). MR images showed a lower transparency in transplanted (Tx) lungs (c) when compared with Tx lung from animals that were inhibited (d) (n =
4). H&E sections from transplanted (Tx) lungs (e) show more perivascular (arrow) and oedema of the alveolar wall (e) when compared with Tx lung from animals
that were inhibited (f ) (n = 6) (magniﬁcation: ×100).
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of SDF-1 in Tx lungs that were exposed to 6 h ischaemia time.
Systemic DPP-4 inhibition in the recipient led to an even larger
increase in SDF-1 levels within the engrafted organ. The lack of
DPP-4 enzymatic activity in CD26/DPP-4 KO mice might be the
reason for the high SDF-1 concentrations in these animals.
CXCR4, the SDF-1 receptor, was strikingly upregulated in the
peripheral blood upon DPP-4 inhibition, which we interpret as
an enhanced response to its active ligand SDF-1. A study by Xu
et al. [24] aimed at reducing cell inﬁltration upon
CXCR4-inhibition in the allogeneic heterotopic model of tra-
cheal implantation in order to lower the inﬂammatory milieu
within the graft. In their study, they found less inﬁltration by
T-cells that were recruited into the graft during chronic rejection.
In contrast to allorejection where T-cell plays the major role of
host defence, I/R injury primarily relies on inﬁltrating innate in-
ﬂammatory cells with subsequent damage to the endothelium
[25]. That is why we were particularly interested in endothelial
progenitor cells that have regenerative capacity, of which CD34
is the key marker. Malfunction of the engrafted organ is reﬂected
by the induction and release of reactive oxygen species and
ischaemia-induced oedema with subsequent swelling of endo-
thelial cells that contributes to damage of the transplant. In fact,
when CD34+ endothelial progenitor cells were co-stained along
with the homing receptor CXCR4 for SDF-1, we found
co-expression for both markers on a higher number of cells in
Tx-inhibited versus Tx grafts. The presence of the markers CD34
and CXCR4 on CD45+ cells in the Tx-inhibited circulation and
lungs was highly suggestive of an increased homing into the pul-
monary graft. This could also be shown for the tyrosine kinase
receptor Flt-3, an early acting factor that supports the survival,
proliferation and differentiation of primitive haematopoietic pro-
genitor cells. Taken together, the recruitment of these progenitor
cells into the engrafted lung led to a considerable improvement
of the histomorphology of the transplant that exhibited less
oedema of the alveolar wall and a preserved endothelial lining.
However, the exact mechanism by which the enhanced SDF-1–
CXCR4 axis is exerting its effect remains largely unclear from our
study. Possible explanations include the prevention of apoptosis
of endothelial cells or apoptotic endothelial cells being replaced
by intact CD34+ endothelial cells that were homed to the injured
alveolar bed. Another possibility is that niches of progenitor cells
with the potency of renewal in the transplanted graft take over
the endothelial function. Alternatively, an enhancement of neo-
vascularization of the capillary bed leading to reformed intact
tissue could occur.
Although we could show a direct correlation between increased
SDF-1 levels and enhanced levels of CXCR4, we did not present
direct evidence that the inhibition of CD26/DPP-4 with subse-
quent decreased cleavage and stabilization of intact SDF-1 was re-
sponsible for the observed effects. The differentiation between
cleaved and uncleaved SDF-1 in biological samples will be part of
our future work. Also, the exact mechanism by which the endo-
thelial damage is reduced still has to be further investigated.
Finally, we aim to explore whether the observed effect of the
enhanced SDF-1–CXCR4 axis can be kinetically followed beyond
48 h, in order to evaluate long-term effects.
The major advantage of the concept presented in this study is
the non-invasive approach. Here, regenerative stem cells can be
endogenously accumulated by enhancing the SDF-1–CXCR4 axis
using a DPP-4 inhibitor. In contrast, conventional stem-cell
therapy essentially relies on the exogenous application of regen-
erative stem cells. Our study surpasses the established clinical
therapeutic concept of the treatment of type II diabetes with
DPP-4 inhibitors and the ongoing trials targeting DPP-4/CD26 as
a promising therapeutic strategy to stabilize the SDF-1–CXCR4
axis after myocardial ischaemia. We feel that our data encourage
further deciphering of the mechanisms ﬁnally leading to an im-
provement of I/R injury after lung transplantation.
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Experimental lung transplantation in mice has been deemed
‘infeasible’ for many years and has been cracked technically
only a few years ago by some extraordinarily dedicated
researchers. Okazaki and colleagues published the ﬁrst experi-
mental report based on a series of successful murine left lung
transplants in 2007 [1, 2]. While other animal models may
more closely resemble the human setting, mouse models have
huge advantages when it comes to the study of mechanistic
questions on the molecular level. Gene knockout mice have
revolutionized whole areas of medical and basic science re-
search and are of no lesser value in transplantation research.
Above that, reagents needed for in vivo treatment, such as de-
pleting antibodies, proteins or peptides, are easily available is
sufﬁcient quantities for mice, but not necessarily for larger
animals. The murine heterotopic (non-vascularized) trachea
transplantation model was used as an approximation to experi-
mental lung transplantation in mice resembling bronchiolitis
obliterans [3], but remains a contraption with severe methodo-
logical shortcomings. With the advent of orthotopic mouse
lung transplantation, this ﬁeld of transplantation surgery is now
accessible to the modern tools of mechanistic life sciences,
and the study by Jungraithmayr et al. [4] in this issue is a
good example of this recent development.
CD26, also called dipeptidyl peptidase-4 (DPP4) is a protein
expressed on many cell types including lymphocytes and lung
parenchyma. It is a membrane glycoprotein with a cell surface
epitope acting as an antigen detectable by the respective
monoclonal antibodies. Its function is the enzymatic cleavage
of certain dipeptides from polypeptides such as growth factors,
chemokines and neuropeptides. This degradation inactivates
the respective polypeptides. Apparently, CD26/DPP4 cleaves a
wide variety of substrates, interfering with many biological
pathways including, for example, glucose metabolism and sup-
pression of cancer development. Stromal cell-derived factor 1
(SDF-1, also called CXCL12) is a substrate of CD26/DPP4.
Jungraithmayr et al. deem SDF-1, together with its receptor
CXCR4, important in the modulation of stem cell homing in
response to ischaemic injury of the lung. In their experimental
setting, they make use of CD26/DPP4 knockout mice, of in
vivo inhibition of CD26/DPP4 activity using vildagliptin and of
a murine orthotopic lung transplantation model to induce
ischaemia-reperfusion injury.
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